What's in Life Molecular Imaging SA's pipeline?

Life Molecular Imaging SA has 5 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Life Molecular Imaging SA's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/life-molecular-imaging-sa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Life Molecular Imaging SA — Portfolio Competitive Intelligence Brief

Life Molecular Imaging SA pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Florbetaben (BAY94-9172)	Florbetaben (BAY94-9172)	phase 3	PET imaging agent / amyloid tracer	Amyloid-beta plaques	Neurology / Diagnostic Imaging

Therapeutic area mix

Neurology / Diagnostic Imaging · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Life Molecular Imaging SA:

Cite this brief

Drug Landscape (2026). Life Molecular Imaging SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/life-molecular-imaging-sa. Accessed 2026-05-16.